Showing results (21-30 of 60) with videos related to
Sort By:
Pageof 6
Cancer Research|January 17, 2015
ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptorsLoredana Cifaldi, Paolo Romania, Michela Falco, et al.Blood|March 6, 2004
Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defectAngela Gismondi, Loredana Cifaldi, Cinzia Mazza, et al.Current Opinion in Pharmacology|September 14, 2021
Polyphenols affect the humoral response in cancer, infectious and allergic diseases and autoimmunity by modulating the activity of TH1 and TH2 cellsMonica Benvenuto, Chiara Focaccetti, Sara Ciuffa, et al.Journal of Translational Medicine|June 26, 2026
Single-cell profiling reveals a novel CAF subpopulation linking stromal heterogeneity to immune suppression in breast cancer subtypesVirginia Vigiano Benedetti, Federica Conte, Daniele Santoni, et al.Frontiers in Medicine|February 23, 2023
Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinomaCamilla Palumbo, Monica Benvenuto, Chiara Focaccetti, et al.Frontiers in Immunology|August 15, 2022
DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept studyChiara Focaccetti, Monica Benvenuto, Chiara Pighi, et al.Frontiers in Immunology|July 3, 2025
A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptorsPaolo Romania, Loredana Cifaldi, Paula Gragera, et al.Cancer Research|January 22, 2011
Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processingLoredana Cifaldi, Elisa Lo Monaco, Matteo Forloni, et al.Cancer Research|January 28, 2010
NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cellsMatteo Forloni, Sonia Albini, Maria Zaira Limongi, et al.Oncoimmunology|July 7, 2017
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastomaElisa Brandetti, Irene Veneziani, Ombretta Melaiu, et al.Pageof 6